In the Thomas Weisel conference, the CEO seemed very positive about Ketotransdel, IMO. If I remember correctly, the CEO said that the next illness they will develop a drug for with their topical Transdel technology is for Osteoarthritis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.